Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adagene Inc. (ADAG)

1.53   0.06 (4.08%) 09-29 09:37
Open: 1.53 Pre. Close: 1.47
High: 1.53 Low: 1.53
Volume: 991 Market Cap: 67(M)

Technical analysis

as of: 2023-09-29 4:25:40 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 1.82     One year: 2.12
Support: Support1: 1.27    Support2: 1.1
Resistance: Resistance1: 1.55    Resistance2: 1.82
Pivot: 1.4
Moving Average: MA(5): 1.43     MA(20): 1.39
MA(100): 1.36     MA(250): 1.39
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 86.8     %D(3): 69.4
RSI: RSI(14): 61.6
52-week: High: 2.09  Low: 0.89
Average Vol(K): 3-Month: 12 (K)  10-Days: 7 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ADAG ] has closed below upper band by 5.6%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.53 - 1.54 1.54 - 1.55
Low: 1.51 - 1.52 1.52 - 1.53
Close: 1.52 - 1.53 1.53 - 1.54

Company Description

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Headline News

Wed, 27 Sep 2023
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Nasdaq

Fri, 08 Sep 2023
天演藥業(Adagene Inc., NASDAQ:ADAG)宣佈將於九月出席多個 ... - 新浪香港

Thu, 07 Sep 2023
Adagene to Present at Investor and Scientific Conferences in ... - BioSpace

Thu, 31 Aug 2023
Adagene Reports Six Month Financial Results for 2023 and ... - GlobeNewswire

Wed, 05 Jul 2023
Healthcare Stocks Making Moves Wednesday: IMPL, ALLR, CBUS, IMUX, XXII, SAVA, BTCY, ADAG - InvestorsObserver

Thu, 04 May 2023
Adagene Achieves $3 Million Milestone in Collaboration with ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 44 (M)
Shares Float 17 (M)
% Held by Insiders 10.5 (%)
% Held by Institutions 9.5 (%)
Shares Short 29 (K)
Shares Short P.Month 20 (K)

Stock Financials

EPS -0.8
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.88
Profit Margin (%) -160.8
Operating Margin (%) -180.5
Return on Assets (ttm) -16.3
Return on Equity (ttm) -37.3
Qtrly Rev. Growth 340.8
Gross Profit (p.s.) 0
Sales Per Share 0.51
EBITDA (p.s.) -0.9
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.94
PEG Ratio 0
Price to Book value 0.8
Price to Sales 2.95
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.